shroom family member 3Genealiases: APXL3 · MSTP013 · SHRM · ShrmL
Q-omics provides the consensus-scored SHROOM3 profile across patient tissues and cancer cell-line models. SHROOM3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHROOM3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SHROOM3 protein abundance shows 20,163 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where SHROOM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHROOM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHROOM3 survival associations across molecular data types. SHROOM3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHROOM3 RNA expression–survival associations across cancer types. High SHROOM3 expression shows unfavorable associations in ACC, LGG, CESC and PAAD, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHROOM3 RNA expression.
This table summarizes SHROOM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SHROOM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHROOM3 shows lower tumor expression in KIRC, HNSC, LUSC, BLCA and COAD and higher tumor expression in STAD. The KIRC box plot shows higher SHROOM3 RNA expression in normal versus tumor tissue (log2 FC = −2.507, t-test p < 0.001).
This table shows molecular features associated with SHROOM3 in patient tissues and cancer cell lines. In patient samples, SHROOM3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHROOM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
